; (ii) biosimilar biological product application fees under subsection (a)(2); and (iii) biosimilar biological product program fees under subsection (a)(3). (B) Limitations on fee amounts Until the first fiscal year for which the capacity planning adjustment under subsection (c)(2) is effective, the amount of any fee under subsection (a) for a fiscal year after fiscal year 2018 shall not exceed 125 percent of the amount of such fee for fiscal year 2018. (C) Biosimilar biological product development fees The initial biosimilar biological product development fee under subsection (a)(1)(A) for a fiscal year shall be equal to the annual biosimilar biological product development fee under subsection (a)(1)(B) for that fiscal year. (D) Reactivation fee The reactivation fee under subsection (a)(1)(D) for a fiscal year shall be equal to twice the amount of the annual biosimilar biological product development fee under subsection (a)(1)(B) for that fiscal year. (4) Annual base revenue For purposes of paragraph (2), the dollar amount of the annual base revenue for a fiscal year shall be the dollar amount of the total revenue amount for the previous fiscal year, excluding any adjustments to such revenue amount under subsection (c)(3). . (c) Adjustments; annual fee setting Section 744H of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–52 ) is amended— (1) by redesignating subsections (c) through (h) as subsections (d) through (i), respectively; (2) in subsections (a)(2)(F) and (g), by striking subsection (c) and inserting subsection (d) ; (3) in subsection (a)(4)(A), by striking subsection (b)(1)(F) and inserting subsection (c)(5) ; and (4) by inserting after subsection (b) the following: (c) Adjustments; annual fee setting (1) Inflation adjustment (A) In general For purposes of subsection (b)(2)(B), the dollar amount of the inflation adjustment to the annual base revenue for each fiscal year shall be equal to the product of— (i) such annual base revenue for the fiscal year under subsection (b)